These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11929843)

  • 1. Correspondence re: A. Kumar et al., cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res., 61: 7552-7555, 2001.
    Garattini E; Gianni' M; Terao M
    Cancer Res; 2002 Apr; 62(7):2192-3; author reply 2193-4. PubMed ID: 11929843
    [No Abstract]   [Full Text] [Related]  

  • 2. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors.
    Holmes WF; Dawson MI; Soprano RD; Soprano KJ
    J Cell Physiol; 2000 Oct; 185(1):61-7. PubMed ID: 10942519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells.
    Jiang T; Soprano DR; Soprano KJ
    J Cell Physiol; 2007 Sep; 212(3):771-9. PubMed ID: 17474084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence supporting a role for mitochondrial respiration in apoptosis induction by the synthetic retinoid CD437.
    Hail N; Youssef EM; Lotan R
    Cancer Res; 2001 Sep; 61(18):6698-702. PubMed ID: 11559538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
    Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
    Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoids and ovarian cancer.
    Zhang D; Holmes WF; Wu S; Soprano DR; Soprano KJ
    J Cell Physiol; 2000 Oct; 185(1):1-20. PubMed ID: 10942515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line.
    Holmes WF; Soprano DR; Soprano KJ
    J Biol Chem; 2002 Nov; 277(47):45408-19. PubMed ID: 12237293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.
    Parrella E; Giannì M; Fratelli M; Barzago MM; Raska I; Diomede L; Kurosaki M; Pisano C; Carminati P; Merlini L; Dallavalle S; Tavecchio M; Rochette-Egly C; Terao M; Garattini E
    Mol Pharmacol; 2006 Sep; 70(3):909-24. PubMed ID: 16788091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor-independent induction of apoptosis by synthetic retinoids.
    Lotan R
    J Biol Regul Homeost Agents; 2003; 17(1):13-28. PubMed ID: 12757019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines.
    Holmes WF; Soprano DR; Soprano KJ
    J Cell Physiol; 2004 Jun; 199(3):317-29. PubMed ID: 15095280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
    Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
    Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR.
    Holmes WF; Soprano DR; Soprano KJ
    J Cell Biochem; 2003 May; 89(2):262-78. PubMed ID: 12704790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
    Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
    Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo.
    Langdon SP; Rabiasz GJ; Ritchie AA; Reichert U; Buchan P; Miller WR; Smyth JF
    Cancer Chemother Pharmacol; 1998; 42(5):429-32. PubMed ID: 9771960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
    Metzinger DS; Taylor DD; Gercel-Taylor C
    Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
    Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
    Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.